421 related articles for article (PubMed ID: 34576069)
1. Cognitive Deficit in Schizophrenia: From Etiology to Novel Treatments.
Martínez AL; Brea J; Rico S; de Los Frailes MT; Loza MI
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576069
[TBL] [Abstract][Full Text] [Related]
2. Pharmacotherapy of cognitive deficits in schizophrenia.
Opler LA; Medalia A; Opler MG; Stahl SM
CNS Spectr; 2014 Apr; 19(2):142-56. PubMed ID: 24229725
[TBL] [Abstract][Full Text] [Related]
3. [Research progress in mechanisms and clinical application for blonanserin and lurasidone in improving cognitive function of schizophrenia].
Zheng Q; Liu B; Xu S; Liao M; Zhang Y; Li L
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Apr; 42(4):476-480. PubMed ID: 28490709
[TBL] [Abstract][Full Text] [Related]
4. Initiatives to promote the discovery of drugs to improve cognitive function in severe mental illness.
Marder SR
J Clin Psychiatry; 2006 Jul; 67(7):e03. PubMed ID: 17107228
[TBL] [Abstract][Full Text] [Related]
5. Behavioral response inhibition in psychotic disorders: diagnostic specificity, familiality and relation to generalized cognitive deficit.
Ethridge LE; Soilleux M; Nakonezny PA; Reilly JL; Hill SK; Keefe RS; Gershon ES; Pearlson GD; Tamminga CA; Keshavan MS; Sweeney JA
Schizophr Res; 2014 Nov; 159(2-3):491-8. PubMed ID: 25261042
[TBL] [Abstract][Full Text] [Related]
6. The deficit syndrome in schizophrenia: implications for the treatment of negative symptoms.
Arango C; Buchanan RW; Kirkpatrick B; Carpenter WT
Eur Psychiatry; 2004 Feb; 19(1):21-6. PubMed ID: 14969777
[TBL] [Abstract][Full Text] [Related]
7. ECNP consensus meeting. Negative, depressive and cognitive symptoms of schizophrenia. Nice, March 2004.
Montgomery SA; van Zwieten-Boot B
Eur Neuropsychopharmacol; 2007 Jan; 17(1):70-7. PubMed ID: 16842980
[No Abstract] [Full Text] [Related]
8. Cognitive effects of second-generation antipsychotics: current insights into neurochemical mechanisms.
Fumagalli F; Frasca A; Racagni G; Riva MA
CNS Drugs; 2009; 23(7):603-14. PubMed ID: 19552487
[TBL] [Abstract][Full Text] [Related]
9. [Results and promises of genetics of cognitive impairment in schizophrenia: molecular-genetic approaches].
Alfimova MV; Kondratiev NV; Golimbet VE
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(11):137-144. PubMed ID: 28635752
[TBL] [Abstract][Full Text] [Related]
10. Harnessing cognitive neuroscience to develop new treatments for improving cognition in schizophrenia: CNTRICS selected cognitive paradigms for animal models.
Moore H; Geyer MA; Carter CS; Barch DM
Neurosci Biobehav Rev; 2013 Nov; 37(9 Pt B):2087-91. PubMed ID: 24090823
[TBL] [Abstract][Full Text] [Related]
11. [Subjective cognitive disorders in schizophrenia].
Peralta Martín V; Cuesta Zorita MJ
Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1993; 21(1):14-20. PubMed ID: 8499035
[TBL] [Abstract][Full Text] [Related]
12. Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia.
Carbon M; Correll CU
CNS Spectr; 2014 Dec; 19 Suppl 1():38-52; quiz 35-7, 53. PubMed ID: 25403863
[TBL] [Abstract][Full Text] [Related]
13. Cognitive enhancement in schizophrenia: pharmacological and cognitive remediation approaches.
Harvey PD; Bowie CR
Psychiatr Clin North Am; 2012 Sep; 35(3):683-98. PubMed ID: 22929873
[TBL] [Abstract][Full Text] [Related]
14. Neuroimaging-genetic paradigms: a new approach to investigate the pathophysiology and treatment of cognitive deficits in schizophrenia.
Roffman JL; Weiss AP; Goff DC; Rauch SL; Weinberger DR
Harv Rev Psychiatry; 2006; 14(2):78-91. PubMed ID: 16603474
[TBL] [Abstract][Full Text] [Related]
15. Practice principles of cognitive enhancement therapy for schizophrenia.
Hogarty GE; Flesher S
Schizophr Bull; 1999; 25(4):693-708. PubMed ID: 10667740
[TBL] [Abstract][Full Text] [Related]
16. Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment.
Sharma T; Antonova L
Psychiatr Clin North Am; 2003 Mar; 26(1):25-40. PubMed ID: 12683258
[TBL] [Abstract][Full Text] [Related]
17. Treatment of cognitive dysfunction in schizophrenia.
Peuskens J; Demily C; Thibaut F
Clin Ther; 2005; 27 Suppl A():S25-37. PubMed ID: 16198199
[TBL] [Abstract][Full Text] [Related]
18. Cognition in schizophrenia.
Harvey PD; Bowie CR; Friedman JI
Curr Psychiatry Rep; 2001 Oct; 3(5):423-8. PubMed ID: 11559481
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial.
Keefe RS; Malhotra AK; Meltzer HY; Kane JM; Buchanan RW; Murthy A; Sovel M; Li C; Goldman R
Neuropsychopharmacology; 2008 May; 33(6):1217-28. PubMed ID: 17625502
[TBL] [Abstract][Full Text] [Related]
20. [Cognition, schizophrenia and the effect of antipsychotics].
Stip E
Encephale; 2006; 32(3 Pt 1):341-50. PubMed ID: 16840928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
